Stocks
BioXcel Financial Statements (BTAI) |
||||||||||
| BioXcelsmart-lab.ru | % | 2023Q1 | 2023Q2 | 2023Q3 | 2023Q4 | 2024Q1 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 09.05.2023 | 14.08.2023 | 30.09.2023 | 22.03.2024 | 09.05.2024 | 09.05.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 0.206 | 0.457 | 0.341 | 0.376 | 0.582 | 1.76 | |||
| Operating Income, bln rub | -51.2 | -52.4 | -48.3 | -19.7 | -23.9 | -144.4 | ||||
| EBITDA, bln rub | ? | -49.4 | -50.2 | -43.0 | -19.7 | -23.9 | -136.7 | |||
| Net profit, bln rub | ? | -51.0 | -53.5 | -50.5 | -22.3 | -26.8 | -153.0 | |||
| OCF, bln rub | ? | -52.4 | -38.2 | -37.6 | -26.9 | -17.7 | -120.4 | |||
| CAPEX, bln rub | ? | 0.000 | 0.020 | 0.000 | 0.000 | 0.000 | 0.020 | |||
| FCF, bln rub | ? | -52.4 | -38.2 | -37.6 | -26.9 | -17.7 | -120.4 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 51.4 | 52.8 | 44.0 | 19.3 | 24.4 | 140.5 | ||||
| Cost of production, bln rub | 0.009 | 0.026 | 0.512 | 0.792 | 0.158 | 1.49 | ||||
| R&D, bln rub | 27.8 | 27.0 | 19.6 | 9.73 | 11.1 | 67.5 | ||||
| Interest expenses, bln rub | 3.37 | 3.26 | 3.25 | 3.44 | 3.61 | 13.6 | ||||
| Assets, bln rub | 180.1 | 140.1 | 100.4 | 73.7 | 82.3 | 82.3 | ||||
| Net Assets, bln rub | ? | 53.0 | 5.86 | -40.6 | -56.5 | -72.4 | -72.4 | |||
| Debt, bln rub | 96.1 | 97.8 | 99.6 | 101.4 | 102.3 | 102.3 | ||||
| Cash, bln rub | 165.5 | 127.5 | 90.0 | 65.2 | 74.1 | 74.1 | ||||
| Net debt, bln rub | -69.4 | -29.8 | 9.66 | 36.2 | 28.2 | 28.2 | ||||
| Ordinary share price, rub | 18.7 | 6.66 | 2.53 | 2.95 | 2.82 | 4.00 | ||||
| Number of ordinary shares, mln | 28.6 | 29.2 | 29.3 | 29.4 | 30.9 | 30.9 | ||||
| Market cap, bln rub | 534 | 194 | 74 | 87 | 87 | 123 | ||||
| EV, bln rub | ? | 465 | 165 | 84 | 123 | 115 | 152 | |||
| Book value, bln rub | 53 | 6 | -41 | -57 | -72 | -72 | ||||
| EPS, rub | ? | -1.78 | -1.83 | -1.72 | -0.76 | -0.87 | -4.96 | |||
| FCF/share, rub | -1.83 | -1.31 | -1.28 | -0.91 | -0.57 | -3.90 | ||||
| BV/share, rub | 1.85 | 0.20 | -1.39 | -1.92 | -2.34 | -2.34 | ||||
| EBITDA margin, % | ? | -23 995% | -10 979% | -12 608% | -5 226% | -4 098% | -7 783% | |||
| Net margin, % | ? | -24 770% | -11 710% | -14 805% | -5 919% | -4 603% | -8 716% | |||
| FCF yield, % | ? | -29.1% | -82.5% | -225.3% | -178.4% | -138.3% | -97.5% | |||
| ROE, % | ? | -363.7% | -3 534% | 524.8% | 313.7% | 211.5% | 211.5% | |||
| ROA, % | ? | -107.0% | -147.9% | -212.2% | -240.5% | -185.9% | -185.9% | |||
| P/E | ? | -2.77 | -0.94 | -0.35 | -0.49 | -0.57 | -0.81 | |||
| P/FCF | -3.44 | -1.21 | -0.44 | -0.56 | -0.72 | -1.03 | ||||
| P/S | ? | 919.1 | 187.3 | 59.6 | 63.0 | 49.6 | 70.3 | |||
| P/BV | ? | 10.1 | 33.1 | -1.82 | -1.54 | -1.20 | -1.71 | |||
| EV/EBITDA | ? | -2.63 | -0.86 | -0.43 | -0.76 | -0.84 | -1.11 | |||
| Debt/EBITDA | 0.39 | 0.16 | -0.05 | -0.22 | -0.21 | -0.21 | ||||
| R&D/CAPEX, % | 134 865% | 337 300% | ||||||||
| CAPEX/Revenue, % | 0.00% | 4.38% | 0.00% | 0.00% | 0.00% | 1.14% | ||||
| BioXcel shareholders | ||||||||||
